Spyre Therapeutics Jumps As SPY001 Meets Key Goal In Phase 2 SKYLINE Trial For Ulcerative Colitis

Spyre Therapeutics reported positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY001, with the study meeting its primary endpoint in moderate-to-severely active ulcerative colitis. The result is a meaningful clinical readout for the biotech and supports the program’s development outlook. While specific efficacy numbers were not provided here, the data are clearly favorable and could support shares.

Analysis

Spyre Therapeutics reported positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY001, with the study meeting its primary endpoint in moderate-to-severely active ulcerative colitis. The result is a meaningful clinical readout for the biotech and supports the program’s development outlook. While specific efficacy numbers were not provided here, the data are clearly favorable and could support shares.